🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#BreakingNews: Today Japan’s Ministry of Health, Labour and Welfare (MHLW) approved our new treatment for adults with chronic inflammatory demyelinating polyneuropathy (#CIDP). #TogetherWeDiscover

Disruptive in our innovation mission, we are committed to pioneering transformative #immunology treatments. Vision 2030 embodies this commitment: reaching 50,000 patients across 10 indications by 2030. #TogetherWeDiscover

As our COO Karen Massey shares, patient needs guide all that we do – from early development to delivering innovative treatments. This #RareDiseaseAwarenessMonth, we’re highlighting the critical need for a patient-centric approach in rare disease care. #TogetherWeDiscover

Our full year and 2024 Q4 earnings report is now available. In 2024, we established strategic priorities to advance Vision 2030 and continued investing in our Immunology Innovation Program (IIP) to drive long-term growth across our pipeline. #TogetherWeDiscover

Today we announced that clinical trial and real-world data showcasing our focus on immunology innovation to drive autoimmune patient impact will be presented at the @AANMember Annual Meeting in April. #TogetherWeDiscover #AAN2025

📢 Our 2024 Annual Report is now available. We’re eager to build upon the progress made in 2024 to continue advancing our Vision 2030 goal of reaching 50,000 patients globally. #TogetherWeDiscover

📢 At #AAN2025, we’re presenting 15 abstracts, including one oral presentation, focused on our innovative approach to autoimmune disease treatment – featuring sustained efficacy and safety for patients with gMG and CIDP, and progress across our pipeline. #TogetherWeDiscover

On a quest to push the boundaries of immunology innovation 🚀! We’re at the @AANMember Annual Meeting, sharing the latest progress in advancing treatment options for autoimmune patients. #TogetherWeDiscover #AAN2025

Today the FDA approved a new option for patients to self-inject with a prefilled syringe for adults with generalized myasthenia gravis (#gMG) who are AChR antibody positive and adults with chronic inflammatory demyelinating polyneuropathy (#CIDP). #TogetherWeDiscover

#NEWS: Now published in Annals of Clinical and Translational Neurology, our ADAPT NXT Part A study adds to an exciting body of research across a broad population of gMG patients. #TogetherWeDiscover

The CHMP adopted a positive opinion, recommending European Commission (EC) approval of a new treatment for adults with progressive or relapsing active CIDP after prior treatment with corticosteroids or immunoglobulins. #TogetherWeDiscover

📢 Our Q1 2025 earnings report is now available. This quarter, we advanced our Vision 2030 goal of delivering innovative therapies to patients worldwide through pipeline advancements and sustained investment in our Immunology Innovation Program. #TogetherWeDiscover

This week we attended the Myasthenia Gravis Foundation of America International Conference, where we shared insights with MG patients. We’re committed to advancing the science for people with MG and other autoimmune diseases. #TogetherWeDiscover

At the Peripheral Nerve Society (PNS) Annual Meeting, we reinforced our commitment to addressing unmet needs in CIDP, MMN, and other autoimmune conditions. Grounded in science and driven by innovation, we’re working to close these gaps with cutting edge research. #TogetherWeDiscover #PNS2025

At #EULAR2025, we’re sharing positive Phase 2 data in Sjogren’s disease and myositis – underscoring our commitment to new therapeutic areas in rheumatology and broadening our research across autoimmune diseases with high unmet need. #TogetherWeDiscover

#NEWS: The European Commission has approved a new treatment for adults with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. #TogetherWeDiscover

We’re advancing ARGX-119 to a registrational study in patients with CMS based on Phase 1b topline data. Favorable safety and tolerability results support this next step in our mission to develop innovative treatments for patients worldwide. #TogetherWeDiscover